MarketPulse
A

$ATRA

26 articles found
0 positive
25 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Alleges Atara Biotherapeutics Concealed Manufacturing and Trial Defects

Class action lawsuit filed against Atara Biotherapeutics for allegedly misrepresenting manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Faces Securities Lawsuit Over Tabelecleucel Manufacturing Claims

Rosen Law Firm urges $ATRA investors to join class action alleging false statements about manufacturing and regulatory prospects for tabelecleucel drug.
ATRAsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ardelyx Appoints Seasoned Biotech Executive Rajani Dinavahi as Chief Medical Officer

Ardelyx appoints Dr. Rajani Dinavahi, veteran biotech executive from Amgen and Atara Biotherapeutics, as Chief Medical Officer to lead clinical strategy and pipeline advancement.
AMGNATRAARDXclinical developmentleadership appointment
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Atara Stock Crashes on FDA Rejection; Class Action Lawsuit Filed Over Alleged Disclosure Failures

Robbins LLP files class action against $ATRA over undisclosed manufacturing issues tied to FDA rejection of lead drug tabelecleucel, citing 57% stock plunge.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Hit With Securities Lawsuit Over Tabelecleucel Drug Claims

Rosen Law Firm sues Atara Biotherapeutics for allegedly misrepresenting tabelecleucel drug's regulatory prospects and manufacturing capabilities to investors between May 2024 and January 2026. Lead plaintiff deadline set for May 22, 2026.
ATRAsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Hit With Class Action Over Misleading FDA Study Claims

Class action lawsuit filed against $ATARAWITH alleging executives made false statements about manufacturing issues and ALLELE study deficiencies that could block FDA approval of tabelecleucel.
ATRAsecurities fraudclass action lawsuit